Chronic Myelogenous Leukemia Treatment

Chronic Myelogenous Leukemia Treatment

Global Chronic Myelogenous Leukemia Treatment Market to Reach $9 Billion by 2030
The global market for Chronic Myelogenous Leukemia Treatment estimated at US$6.3 Billion in the year 2023, is expected to reach US$9 Billion by 2030, growing at a CAGR of 5.3% over the period 2023-2030. Disease Specific Treatment, one of the segments analyzed in the report, is expected to record 6% CAGR and reach US$3.1 Billion by the end of the analysis period. Growth in the Symptomatic Treatment segment is estimated at 5% CAGR for the next 7-year period.

The U.S. Market is Estimated at $1.9 Billion, While China is Forecast to Grow at 4.9% CAGR
The Chronic Myelogenous Leukemia Treatment market in the U.S. is estimated at US$1.9 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 4.9% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.1% and 4.3% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR.

What to Expect from the Global Economy in 2024
Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.

Select Competitors (Total 42 Featured) -
  • Bio-Path Holdings, Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG
  • Incyte Corporation
  • Novartis AG
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Chronic Myelogenous Leukemia Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
Global Economic Update
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 2: World Historic Review for Chronic Myelogenous Leukemia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 3: World 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Disease Specific Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 5: World Historic Review for Disease Specific Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 6: World 16-Year Perspective for Disease Specific Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 7: World Recent Past, Current & Future Analysis for Symptomatic Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 8: World Historic Review for Symptomatic Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 9: World 16-Year Perspective for Symptomatic Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Branded by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 11: World Historic Review for Branded by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 12: World 16-Year Perspective for Branded by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 13: World Recent Past, Current & Future Analysis for Generic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 14: World Historic Review for Generic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 15: World 16-Year Perspective for Generic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 16: World Chronic Myelogenous Leukemia Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
Chronic Myelogenous Leukemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 17: USA Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 18: USA Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 19: USA 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2014, 2024 & 2030
TABLE 20: USA Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 21: USA Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 22: USA 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2014, 2024 & 2030
CANADA
TABLE 23: Canada Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 24: Canada Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 25: Canada 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2014, 2024 & 2030
TABLE 26: Canada Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 27: Canada Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: Canada 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2014, 2024 & 2030
JAPAN
Chronic Myelogenous Leukemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 29: Japan Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 30: Japan Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: Japan 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2014, 2024 & 2030
TABLE 32: Japan Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 33: Japan Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: Japan 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2014, 2024 & 2030
CHINA
Chronic Myelogenous Leukemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 35: China Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 36: China Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: China 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2014, 2024 & 2030
TABLE 38: China Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: China Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: China 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2014, 2024 & 2030
EUROPE
Chronic Myelogenous Leukemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 41: Europe Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 42: Europe Historic Review for Chronic Myelogenous Leukemia Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: Europe 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 44: Europe Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: Europe Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: Europe 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2014, 2024 & 2030
TABLE 47: Europe Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: Europe Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: Europe 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2014, 2024 & 2030
FRANCE
Chronic Myelogenous Leukemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 50: France Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: France Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: France 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2014, 2024 & 2030
TABLE 53: France Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 54: France Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: France 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2014, 2024 & 2030
GERMANY
Chronic Myelogenous Leukemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 56: Germany Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: Germany Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: Germany 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2014, 2024 & 2030
TABLE 59: Germany Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 60: Germany Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: Germany 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2014, 2024 & 2030
ITALY
TABLE 62: Italy Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: Italy Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: Italy 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2014, 2024 & 2030
TABLE 65: Italy Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: Italy Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: Italy 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2014, 2024 & 2030
UNITED KINGDOM
Chronic Myelogenous Leukemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 68: UK Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: UK Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: UK 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2014, 2024 & 2030
TABLE 71: UK Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 72: UK Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: UK 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 74: Rest of Europe Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: Rest of Europe Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: Rest of Europe 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2014, 2024 & 2030
TABLE 77: Rest of Europe Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: Rest of Europe Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: Rest of Europe 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Chronic Myelogenous Leukemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 80: Asia-Pacific Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: Asia-Pacific Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: Asia-Pacific 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2014, 2024 & 2030
TABLE 83: Asia-Pacific Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: Asia-Pacific Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: Asia-Pacific 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2014, 2024 & 2030
REST OF WORLD
TABLE 86: Rest of World Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: Rest of World Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: Rest of World 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2014, 2024 & 2030
TABLE 89: Rest of World Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: Rest of World Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: Rest of World 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings